Larazotide(Larazotide), also known as AT-1001, is a peptide compound. It is mainly used to treat increased intestinal permeability caused by diseases. Larazotide inhibits the activity of guanylate cyclase ZOT (zonulin occludens toxin) on the intestinal mucosa to reduce the permeability of the intestinal mucosa, thereby reducing the intestinal absorption of harmful substances.
Larazotide preparation methods mainly include chemical synthesis and genetic engineering technology. The chemical synthesis method is based on the general chemical knowledge of synthetic peptides, including the addition of amino acids, deprotection, coupling and purification steps. Genetic engineering technology utilizes recombinant DNA technology to synthesize the gene of the target peptide by expressing it in bacteria or eukaryotic cells.
In terms of safety, Larazotide have shown good tolerability and safety in clinical trials and previous studies. Common side effects include mild nausea, abdominal pain, and diarrhea, but these are usually short-lived. However, before using this drug, you should still consult a doctor to understand individual fitness and potential risks.